Apr 2, 2024 08:30AM
Dec 4, 2023 08:00AM
Nov 13, 2023 08:00AM
Sep 26, 2023 08:00AM
Aug 14, 2023 08:10AM
May 15, 2023 04:45PM
Apr 25, 2023 08:00AM Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
Apr 25, 2023 08:00AM
Nov 14, 2022 08:30AM
Nov 14, 2022 08:30AM
Apr 25, 2022 08:00AM
Apr 25, 2022 08:00AM
Sep 22, 2020 07:31AM
Sep 22, 2020 07:30AM Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab
Sep 22, 2020 07:30AM
Sep 17, 2020 09:29AM
Sep 17, 2020 08:01AM
Sep 17, 2020 08:00AM
Sep 17, 2020 08:00AM
Jul 7, 2020 07:56AM
Jul 7, 2020 07:55AM Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease
Jul 7, 2020 07:55AM
May 13, 2020 05:02PM
May 13, 2020 05:02PM
Apr 27, 2020 07:46AM
Apr 27, 2020 07:45AM
Apr 27, 2020 07:45AM
Apr 7, 2020 07:55AM Vaccinex Delivers Virtual Presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD™ Focus Meeting 2020
Apr 7, 2020 07:55AM
Feb 6, 2020 07:31AM
Feb 6, 2020 07:31AM
Feb 6, 2020 07:31AM
Nov 11, 2019 05:45AM
Nov 9, 2019 08:02AM
Nov 9, 2019 08:02AM Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Societ
Sep 27, 2019 06:06AM
Sep 27, 2019 06:05AM
Sep 27, 2019 06:05AM
Aug 13, 2019 08:07AM
Aug 13, 2019 08:05AM
Aug 13, 2019 08:05AM
Jun 3, 2019 08:08AM Vaccinex (VCNX) Announces Updated Interim Results from Phase 1b/2 Study of Pepinemab in Combination with Avelumab in NSCLC at ASCO 2019 Meetings
Jun 3, 2019 08:00AM
Jun 3, 2019 08:00AM
Jun 3, 2019 08:00AM

322,900 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All